| scholarly article | Q13442814 |
| P50 | author | Ángeles O Angela Ruiz-Extremera | Q71720473 |
| Julián López-Viota Gallardo | Q79286646 | ||
| P2093 | author name string | Javier Salmerón | |
| Laura Sanjuán-Nuñez | |||
| Rosa Quiles-Perez | |||
| Paloma Muñoz-de-Rueda | |||
| José A Muñoz-Gámez | |||
| Ángel Carazo | |||
| Ángel Delgado | |||
| Andrés Barrientos | |||
| P2860 | cites work | Targeting poly(ADP-ribose) polymerase activity for cancer therapy | Q34204660 |
| Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage | Q34576873 | ||
| CMCTS stabilized Fe3O4 particles with extremely low toxicity as highly efficient near-infrared photothermal agents for in vivo tumor ablation | Q34843802 | ||
| Chemopotentiation by PARP inhibitors in cancer therapy. | Q36136079 | ||
| Role of the peroxynitrite-poly (ADP-ribose) polymerase pathway in the pathogenesis of liver injury | Q36570222 | ||
| Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities | Q36803827 | ||
| Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. | Q36822642 | ||
| Therapeutic applications of PARP inhibitors: anticancer therapy and beyond | Q36853236 | ||
| Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers | Q37178442 | ||
| The safety of the temozolomide in patients with malignant glioma. | Q37239375 | ||
| PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. | Q37442057 | ||
| Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis | Q37684726 | ||
| A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy | Q37844192 | ||
| Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. | Q37844303 | ||
| Promising approaches in using magnetic nanoparticles in oncology | Q37919101 | ||
| Theranostic nanomedicine for cancer detection and treatment | Q38199787 | ||
| Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation. | Q39130328 | ||
| Nanoengineering of doxorubicin delivery systems with functionalized maghemite nanoparticles | Q39136391 | ||
| Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells | Q39629347 | ||
| Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy | Q39754343 | ||
| A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation | Q39773986 | ||
| In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. | Q39894612 | ||
| Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression | Q42831020 | ||
| ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors | Q43236659 | ||
| The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. | Q43246238 | ||
| Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer | Q46163448 | ||
| Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity | Q46768039 | ||
| Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury | Q46842550 | ||
| Nanotechnology: Carrying drugs | Q48317547 | ||
| Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. | Q52087746 | ||
| P433 | issue | 4 | |
| P921 | main subject | cytotoxicity | Q246181 |
| magnetite nanoparticle | Q3870166 | ||
| magnetic nanoparticle | Q117817683 | ||
| P304 | page(s) | 1430-1441 | |
| P577 | publication date | 2014-06-03 | |
| P1433 | published in | Liver International | Q15765078 |
| P1476 | title | Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles | |
| P478 | volume | 35 |
| Q40218092 | Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options |
| Q33828196 | Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro |
| Q26823523 | Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma |
| Q57144042 | PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma |
| Q37372483 | The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids |
Search more.